Corporate Overview

Zero Candida (ZCT) is a publicly traded FemTech company pioneering innovative solutions to address unmet needs in women’s health. The company is developing a tampon-like device that uses artificial intelligence and therapeutic blue light at a precise wavelength and intensity to effectively treat Candida fungus, with a proven 99.999% success rate in POC. 

Vulvo-Vaginal Candidiasis (VVC) affects approximately 75% of women worldwide, and recurrent cases (four or more episodes per year) are increasingly resistant to existing drug treatments, as the root cause remains poorly understood and inadequately addressed. ZCT is following a de novo regulatory pathway and is finalizing the device for human use in preparation for an upcoming clinical trial, after successfully completing a safety trial in large animals (sheep). The company has secured funding and partnerships with leading hospitals in Europe and Israel, while expanding its global patent portfolio with applications filed in the United StatesBrazil, and Europe, and is fully patented in South Africa

With the VVC treatment market projected to exceed USD $2B in the next five years, ZCT is combining hybrid medicine and technology-based diagnostics to improve access to underserved populations and bring gynecology into the 21st century.